Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chemocentryx Inc (CCXI)

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,807,034
  • Shares Outstanding, K 58,048
  • Annual Sales, $ 42,880 K
  • Annual Income, $ -37,970 K
  • 60-Month Beta 2.15
  • Price/Sales 40.12
  • Price/Cash Flow N/A
  • Price/Book 27.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.26
  • Number of Estimates 5
  • High Estimate -0.21
  • Low Estimate -0.32
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -23.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.88 +294.73%
on 11/22/19
36.88 -15.66%
on 11/26/19
+21.74 (+231.96%)
since 11/11/19
3-Month
6.44 +383.00%
on 09/30/19
36.88 -15.66%
on 11/26/19
+23.40 (+303.96%)
since 09/11/19
52-Week
6.16 +404.95%
on 08/06/19
36.88 -15.66%
on 11/26/19
+21.00 (+207.97%)
since 12/11/18

Most Recent Stories

More News
Chemocentryx Inc Set to Possibly Rebound After Yesterday's Selloff of 3.37%

Chemocentryx Inc (NASDAQ:CCXI) traded in a range yesterday that spanned from a low of $28.00 to a high of $29.89. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

CCXI : 31.21 (+0.26%)
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

GBT : 78.45 (+3.29%)
ICPT : 119.36 (+3.90%)
AMGN : 234.01 (+0.07%)
CCXI : 31.21 (+0.26%)
CBAY : 1.70 (unch)
ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock?

ChemoCentryx (CCXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CCXI : 31.21 (+0.26%)
Company News For Nov 27, 2019

Companies In The News Are: TITN, HPE, SAFE, CCXI

HPE : 15.87 (+0.19%)
TITN : 14.00 (+1.67%)
CCXI : 31.21 (+0.26%)
SAFE : 41.11 (-1.32%)
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

Key highlights of the past week include regulatory and pipeline updates.

GBT : 78.45 (+3.29%)
ALXN : 109.50 (-1.53%)
ICPT : 119.36 (+3.90%)
BIIB : 292.23 (-1.67%)
AMGN : 234.01 (+0.07%)
CCXI : 31.21 (+0.26%)
CBAY : 1.70 (unch)
It's Been a Particularly Exciting Year for Biotech Stocks Across the Board

The biotech sector continues to grow as valuations are sky high, based on recent M&A's within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at...

ONCY : 1.12 (+1.82%)
CCXI : 31.21 (+0.26%)
AKRO : 23.00 (-5.54%)
ALXN : 109.50 (-1.53%)
ChemoCentryx Up on Encouraging Rare Disease Candidate Data

ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.

RHHBY : 38.4900 (+0.23%)
ALKS : 20.93 (-2.97%)
BIIB : 292.23 (-1.67%)
CCXI : 31.21 (+0.26%)
CCXI Crosses Above Average Analyst Target

In recent trading, shares of ChemoCentryx, Inc. have crossed above the average analyst 12-month target price of $19.60, changing hands for $30.73/share.

CCXI : 31.21 (+0.26%)
Chemocentryx Inc Rises 279.84% on Heavy Volume: Watch For Potential Pullback

Chemocentryx Inc (NASDAQ:CCXI) traded in a range yesterday that spanned from a low of $30.01 to a high of $36.88. Yesterday, the shares gained 279.8%, which took the trading range above the 3-day high...

CCXI : 31.21 (+0.26%)
ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday,...

CCXI : 31.21 (+0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade CCXI with:

Business Summary

ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

See More

Key Turning Points

2nd Resistance Point 32.62
1st Resistance Point 31.87
Last Price 31.21
1st Support Level 29.99
2nd Support Level 28.86

See More

52-Week High 36.88
Last Price 31.21
Fibonacci 61.8% 25.14
Fibonacci 50% 21.52
Fibonacci 38.2% 17.89
52-Week Low 6.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar